WO1997030658A1 - Systeme d'activation d'une valve cardiaque et valve cardiaque activee. - Google Patents
Systeme d'activation d'une valve cardiaque et valve cardiaque activee. Download PDFInfo
- Publication number
- WO1997030658A1 WO1997030658A1 PCT/FR1997/000312 FR9700312W WO9730658A1 WO 1997030658 A1 WO1997030658 A1 WO 1997030658A1 FR 9700312 W FR9700312 W FR 9700312W WO 9730658 A1 WO9730658 A1 WO 9730658A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- valve
- magnetic
- seat
- valves
- opening
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2403—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with pivoting rigid closure members
Definitions
- the present invention relates to a system for activating a heart valve as well as an activated heart valve.
- Artificial heart valves also called valvular, mitral or aortic prostheses, generally consist of one or two movable valves mounted on a seat by means of one or more joints, said seat being also sutured on the patient's natural pathways.
- the opening and closing phases of the valves have very short durations compared to those which correspond to the blood flow or the obturation, however these opening and closing phases, and the precise moment when they intervene in the cardiac cycle largely determine the quality of the valve.
- the opening and closing mechanisms of a traditional artificial valve are as follows.
- the natural aortic valve opens simultaneously with the reversal of the ventriculo-aortic pressure difference, because being without inertia, it opens under a zero pressure difference unlike a mechanical valve prosthesis. It closes gradually, but quickly and without reflux, at the end of systole under the action of local pressure differences on the sheets which are the equivalent of the valves. These local pressure differences precede the global inversion of the pressure difference between the aorta and the ventricle, an inversion necessary for the initialization of a reflux. This is why the natural aortic valve closes without reflux when the aortic pressure becomes higher than the ventricular pressure while it is the reflux which closes a mechanical valve prosthesis.
- the natural mitral valve opens actively under the effect of the tension of cords attached on the one hand to the edges of its leaves and on the other hand to the internal walls of the ventricle. It is the dilation of the ventricle during diastole that simultaneously causes the fall in ventricular pressure (and therefore the inversion of the difference in atrioventricular pressure) and the opening of the mitral valve by traction on its ropes.
- the opening of the natural mitral valve is therefore strictly synchronous with the inversion of atrioventricular pressure, whereas a mechanical valve prosthesis requires the intervention of a pressure difference to open, and therefore opens in delay.
- mitral valve closes without reflux, as opposed to an artificial valve whose valve (s) are driven throughout their closure by reflux.
- valves of artificial valves therefore have a certain inertia and both their opening and their closing require an energy expenditure taken from the energy of the blood flows. It is clear that this energy which is produced by the heart, then communicated to the blood flows, will have to be all the more important that the loss of tra ⁇ svalvulaire load is great and that the blood reflux, through the valve, at closing, is important.
- the additional cardiac effort thus generated is penalizing for the patient, particularly in the case of mitral valves where the flow rates and therefore the energies of the already weak blood flows naturally are even more so in the presence of cardiac pathologies.
- valve prostheses see the ratio of the refluxing volume to the volume of the flow increasing in a prohibitive way (because the duration of the reflux necessary for the closing of the valves tends to occupy an important place in the cycle).
- one of the valves may not open, which causes thrombosis. This can happen, in particular, when the patient has a pathological low flow cardiac regime and / or adopts a substantially horizontal position.
- the blood flows at the cardiac orifices are not necessarily symmetrical, conventional valve prostheses can therefore have an asymmetrical operation.
- such a mode of operation can be detrimental to the integrity of the valve prosthesis due to the poor distribution of stresses which it then undergoes.
- valves pass directly from a fully open position to a closed position, which requires large and sudden movements of the valves, sometimes causing rupture or premature wear of the valve as well as the appearance of noise and cavitation.
- the invention aims to solve the above problems or at least to mitigate them satisfactorily.
- This object is achieved according to the invention by means of an activation system for a heart valve comprising a seat and at least one pivoting valve mounted on the seat, characterized in that it comprises at least one mobile magnetic element, formed by said valve and possibly at least one fixed magnetic element, integral with the seat, said magnetic elements creating a force which is exerted on said valve during its opening and / or closing movements.
- said mobile magnetic element produces a first magnetic field and said fixed magnetic element produces a second magnetic field.
- the first and second magnetic fields are determined in such a way that their mutual influence creates, when the blood pressure is identical on both sides of the valve, an equilibrium position, towards which the valve is recalled at all moment by said force which varies according to the position of said valve so 7/30658 5 PCI7FR97 / 00312
- This equilibrium position preferably corresponds to an intermediate opening position of the valve. According to an advantageous characteristic, the variations of said force, as a function of the position of the valve, are independent on either side of the equilibrium position.
- said force produces a magnetic torque exerted on the valve, the maximum value of which is between 10 ⁇ 3 e t lO ' ⁇ Nm This torque is less than the blood pressure forces exerted on the valve in its full opening and closing positions.
- the first and second magnetic fields are determined so that the valve pivots in the seat with the minimum of friction.
- the equilibrium position is located between the full opening and closing positions.
- the mutual influence of the first and second magnetic fields produces repulsive magnetic forces between the mobile magnetic element and the fixed magnetic element.
- said fixed magnetic element is integrated into the thickness of the seat, for example, in the vicinity of a joint.
- said movable magnetic element is integrated into the thickness of the valve and sealed so that also avoids contact with the blood.
- the valve is made in the mass with a hemocompatible material allowing the incorporation of magnets without modification of their magnetic characteristics.
- the system comprises a mobile magnetic element and two or three fixed magnetic elements, for each articulation of the valve.
- the fixed magnetic elements are then arranged in a ring around an axis of articulation of the valve.
- said magnetic elements are so-called permanent rare earth magnets, based on Samarium and Cobalt, or based on Neodymium, Iron and Boron.
- Another object of the invention is a heart valve equipped with the activation system described above.
- a particular embodiment of such a valve consists in machining a valve made in the mass of a hemocompatible titanium alloy to form a housing, placing the movable magnetic element in this housing, closing this housing with a cover of the same titanium alloy, and finally hermetically weld this cover to the valve.
- valve of the invention consists in providing it with two valves activated by the only reciprocal influence of the mobile magnetic elements of each valve.
- a second variant consists in producing at least one of the two valves or one of the two seats with a ferromagnetic material, so as to form at least one mobile or fixed magnetic element which does not produce a magnetic field but which is under influence of the magnetic field (s) produced by other mobile or fixed magnetic elements.
- Another variant consists in providing only movable magnetic elements on the valve; the seat then comprising no magnetic element.
- Yet another variant consists in providing for the presence of interactive mobile magnetic elements and the presence on the seat fixed magnetic elements that are inactive, or whose influence is negligible.
- the s y stem Activation of the invention allows, thanks to the intermediate open position of the valve, resulting in pressure equilibrium on either side of the valve, an active valve opening, especially in the mitral position, guaranteeing a symmetrical opening of all the valves, even in the event of very low blood flow, and reducing the reflux on closing. Guaranteed opening of all valves reduces the risk of thrombus formation.
- the valves fitted with these activation systems are controlled by variations in blood pressure, and not by the flow rates as is the case with passive valves, that is to say not activated according to the principle of the invention. Because the flow is itself generated by the pressure variations, it is possible to have anticipated opening and closing phases with respect to the operating sequences of the artificial and traditional valves that are not activated.
- the valves of the activated valves appear to be without inertia for the blood flows which thus conserve all their acquired energy.
- the activation system of the invention also makes it possible to improve the efficiency of the valves by reducing blood reflux. Indeed, the magnetic assistance causes the anticipated closure of the valve even though the rate of blood reflux is still almost zero.
- the jets which occur at the time of closing when it is carried out in the presence of a significant reflux speed (as is the case with the valves not activated) generally involve risks of cavitation and hemolysis which are therefore limited by the use of the invention.
- the opening and closing movements have a first phase which takes place under the impulse of magnetic forces and a second phase which is under the influence of hydraulic forces.
- the automatic return of the valves to the intermediate equilibrium opening position also makes it possible to break down the movements and reduce the speeds at the end of opening and closing, which eliminates violent shocks on the seat, thereby reducing the risks of rupture, noise, cavitation and hemolysis.
- the activation system of the invention allows a greater opening of the valve to reduce the transvalvular pressure loss and this without increasing the reflux thanks to the anticipation of the movement at closing.
- the magnetic activation of the valve has particularly important effects especially in the phases of the cardiac cycle where the hydraulic forces are weak, that is to say between the diastole and the systole and conversely between the systole and the diastole.
- the intensities of the torques and the magnetic forces at play can remain low while being effective. They are therefore not likely to disturb the hydraulic functioning of the valve during the diastolic and systolic phases.
- the values of these couples are not likely to cause any increase in the transvalvular pressure drop, when the valve is open, any more than an increase in the transvalvular leakage flow rate when the valve is closed.
- FIG. 2a and 2b are graphs respectively representing the pressure variations and the ventricular volume variations during the cardiac cycle for the left heart;
- FIG. 3a, 3b, 3c are respectively perspective views, in cross section and in top view of a valve equipped with an embodiment of the activation system of the invention, in the closed position;
- FIG. 4a, 4b, 4c are perspective views respectively, in cross section and in top view of the valve of Figures 3a, 3b, 3c in the intermediate equilibrium position;
- FIGS. 5a, 5b, 5c are respectively perspective views, in cross section and in top view of the valve of Figures 3a, 3b and 3c in the fully open position;
- FIGS. 9, 10 and 11 show the graphs of variations of the magnetic return torque corresponding, respectively, to the magnetic configurations of FIGS. 6, 7 and 8.
- FIGS. 2a and 2b The behavior of the right heart is qualitatively identical to that of the left heart.
- the systole corresponds to the period of ventricular contraction (figures le and ld), while the diastole corresponds to that of the relaxation (figures la and lb).
- the following description will make it possible to locate in the cardiac cycle the opening and closing movements of the aortic and mitral valves previously described.
- the systole phase begins and the ventricle B begins to contract by compressing the blood it contains.
- the ventricular pressure therefore increases very suddenly, almost immediately exceeding the atrial pressure, which causes the closure of the valve VI, facilitated by the equally abrupt release of the tension on the strings (FIG. 1a and point f in FIG. 2a). . Blood reflux to atrium A is no longer possible.
- the aortic valve V2 remains closed. Then the ventricular pressure exceeds the aortic pressure, the valve V2 opens and the ventricular ejection occurs ( Figure 1d and point 0 in Figure 2a).
- the aortic pressure increases but the ventricle B does not empty completely and the maximum aortic pressure is reached before the ejection is completed.
- the flow of blood from ventricle B during the terminal phase of systole is low and less than the flow of blood from the aorta.
- the atrial pressure also increases slowly over the duration of the ejection.
- ventricle B relaxes and the ventricular pressure drops below the aortic pressure, which causes the aortic valve V2 to close (point f, Figure 2a).
- the decreasing ventricular pressure is still greater than the atrial pressure, so that the atrioventricular valve VI remains closed (Figure le).
- valve VI opens (point 0 ', FIG. 2a) and the filling of the ventricle begins again as described previously in relation to the start of the diastole (figure la).
- FIGS. 2a and 2b respectively represent the variations in pressure and ventricular volume during the different phases described above and with reference to FIGS. 1a to 1c as mentioned at the bottom of FIG. 2b. It appears quite clearly in the study of the cardiac cycle that the natural valves are synchronized with the relative pressures prevailing in the atrium, the ventricle and / or the aorta and not with the flow rates. These valves therefore have anticipated opening and closing modes with respect to variations in flow rates. In addition, the opening of the mitral valve is facilitated by ventricular dilation which is accompanied by traction on the tendon cord.
- the activation system of the invention aims to operate the artificial valves, according to opening and closing modes which are very close to those of natural valves.
- valve shown in Figures 3a, 3b and 3c and following is an artificial valve equipped with the activation system of the invention.
- This valve comprises a seat 1, at least one valve and preferably here two valves 2a, 2b identical, mounted on the seat 1 symmetrically, with respect to the diametrical axis XX '.
- Each of the valves 2a, 2b pivots about an axis YY ', parallel and close to the axis XX' by means of two symmetrical articulations, arranged on either side of each valve.
- a joint is, for example, made up of a transverse finger 10 integral with the internal lateral flank of the seat 1 and intended to engage with freedom of relative rotation inside a cylindrical cavity 20 formed in the thickness of the edge lateral of the valve 2a, 2b or in an added boss 21.
- the two valves 2a, 2b come into the closed position ( Figures 3a to 3c), abutted against each other by their respective inner edge 22a, 22b oriented along the axis XX '.
- the inner edges 22a, 22b are chamfered so that in the closed position, the valves 2a, 2b make between them an angle of 2 ⁇ between 90 ° and 180 °.
- the actual activation system comprises, by articulation, on the one hand, at least one and in the embodiment shown, three fixed magnetic elements 3, integral with the seat 1 and at least one mobile magnetic element 4 here carried by the valve 2a, 2b.
- the magnetic elements 3,4 are adapted and intended to create a force which is exerted on the valve 2a, 2b during its opening and / or closing movements.
- the fixed magnetic elements 3 and mobile 4 respectively produce a first and a second magnetic field whose specific characteristics are possibly different.
- These magnetic elements 3, 4 are preferably permanent magnets called rare earths (for example based on Samarium and Cobalt or based on Neodymium of Iron and Boron) with strong magnetizations and coercivities and therefore with great magnetic stability.
- the fixed magnetic elements 3 which are compact and can be integrated into the thickness of the outer flank of the seat 1 and are therefore not likely to come into contact with the blood.
- the fixed magnetic elements 3 can be arranged in a crown as illustrated in particular in FIG. 3b, but they can have any other arrangement favorable for obtaining the desired magnetic fields.
- the first and second magnetic fields are determined so as to produce repulsive magnetic forces between the mobile element 4 and the fixed element 3. These forces have an intensity between 0 and 10 _ lN. These repulsive forces allow both the control of the pivoting of the valve 2a, 2b and the centering of said valve in the seat, this which in particular ensures a minimum of friction.
- the mobile magnetic element 4 is integrated into the thickness of the valve 2a, 2b.
- the movable magnetic element 4 is fixed integrally in a housing 24 formed laterally in the boss 21.
- the housing 24 is itself sealed in a sealed manner by a welded cover (not shown) thereby enclosing the element 4.
- the valves 2a, 2b are, at least as far as the bosses 21, preferably made of a hemocompatible titanium alloy.
- This metal also has the advantage of being light, resistant and allowing both the machining of the housings 24 and the welding of the cover. It also allows, because of its solidity, the production of thinner valves than those existing in traditional materials (for example pyrocarbon), and thus makes it possible to free up a larger passage surface, and therefore to reduce the pressure drop transvalvular.
- the activation system is compatible with any other hemocompatible material (ceramics, metal alloys, pyrolytic carbon ).
- the respective magnetic fields of the fixed 3 and mobile 4 elements are determined in such a way that their reciprocal influence can ensure control of the movements of the valve.
- an equilibrium position E of the valves 2a, 2b is created.
- the valves are returned to this stable equilibrium position E at any time by a force which produces a magnetic torque varying as a function of the angular position of said valves.
- the laws and graphs of the variations of the magnetic return torque are determined so as to minimize the blood reflux without increasing the transvalvular pressure drop.
- these graphs, represented in FIG. 9 (in relation to the embodiment described), are independent on either side of the equilibrium position E.
- the maximum torque is between 10-3 e t lO - Nm
- the equilibrium position E is shown in Figures 4a, 4b and 4c. It corresponds to zero magnetic torque and offers an intermediate opening of the valves, here halfway between the positions closing angles (Figures 3a to 3c) and full opening ( Figures 5a to 5c).
- This intermediate opening generally corresponds to an angle of 2 ⁇ between the valves 2a, 2b between 60 ° and 140 °, the positions of the valves being at all times symmetrical with respect to the diametrical plane D passing through the axis XX '.
- the equilibrium position E of the valves corresponds, here, to an angle ⁇ of 55 °, relative to the base plane S of the seat 1 (see FIG. 9).
- valve is shown with the valves 2a, 2b in the fully open position. In this position, the two valves 2a, 2b are oriented in planes parallel both to each other and to the diametral plane D.
- the mobile magnetic element 4 In the half-opening position corresponding to equilibrium, the mobile magnetic element 4 is oriented opposite but perpendicular to the fixed magnetic element 3 in between.
- the first and second magnetic fields produced respectively by the mobile magnetic element 4 and by the magnetic elements 3 depend, of course, on the respective geometry and the relative positions of said elements 3, 4 as well as their magnetization directions.
- Figures 6, 7 and 8 show only some of the various magnetic configurations of the activation system of the invention. Other configurations are possible allowing, as here, to obtain variations of the booster torque which minimize blood reflux without increasing the transvalvular pressure drop.
- the magnetization vector is always directed towards the magnetic North of the magnet considered.
- the magnetization vectors N of the fixed magnets 31, 32, 33 are oriented positively along the axis of articulation YY ', that is to say from Y to Y'.
- the magnetization vector N * of the mobile magnet 4 is also oriented parallel to the axis of articulation but in the opposite direction, that is to say from Y ′ to Y.
- FIG. 9 represents the graphs of variation of the magnetic torque as a function of the angle ⁇ of the valve relative to the base plane S of the seat 1 (see FIG. 3b, 4b , 5b).
- the fully open position corresponds to an angle ⁇ of 85 °, the equilibrium position E to an angle ⁇ of 55 ° and the closed position to an angle ⁇ of 25 °.
- the magnetic return torque, applied from the closed position to the magnetic equilibrium position E gives the valve an impulse to open it when the pressure difference on either side of the valve is zero, and guides it to 'at its magnetic equilibrium position E.
- the valves open symmetrically, during the downstream flow phase, at least at 55 °, so as to offer the blood an area of significant passage, which guarantees a minimum pressure drop.
- the rest of the opening path (from 55 ° to full opening) is done without significant loss of energy for the flow, because the magnetic forces are very weak compared to the hydraulic forces.
- This example of magnetic assistance corresponds well to the functional requirements of a mitral valve prosthesis.
- FIG. 7 represents a magnetic configuration with two fixed magnets 31, 32 and a movable magnet 4.
- the magnetization vectors N, fixed magnets 31, 32, are oriented along the axis of articulation Y'Y, that is to say, in the direction of Y 'towards Y, contrary to the configuration of the figure 6.
- the magnetization vector N ', of the mobile magnet 4 is oriented along the longitudinal axis AA' of the valve 2a, which makes an angle ⁇ with the base plane S of the seat 1 and towards the free end edge of the said valve.
- the return torque applied from the fully open position to the magnetic equilibrium position E, makes it possible to initiate and then to guide the valve to this position when the transvalvular pressure difference reverses. From this latter position, the movement of the valve to its closed position is almost instantaneous, because the valve offers a large bearing surface for the fluid, and there remains only an angular travel of 10 ° to travel.
- the magnetic return torque towards the magnetic equilibrium position still exists when the valve forms an angle of 90 ° with the base plane S of the seat, the profile of the valve can therefore allow the valves to be opened at 90 °, so to minimize the loss of transvalvular load in the event of high flow, without having to fear an increase in reflux.
- This example of magnetic assistance corresponds well to the functional requirements of an aortic valve prosthesis.
- FIG. 10 represents the graph of the variations of the return torque as a function of the angular position of the valve for the magnetic configuration represented in FIG. 7.
- FIG. 8 represents a magnetic configuration with a fixed magnet 3 and a movable magnet 4.
- the magnetization vector N of the fixed magnet 3 is oriented in a direction d, while the magnetization vector N 'of the movable magnet 4 is oriented according to the normal on the upper surface of the valve 2a. Consequently, the mobile magnet 4 tends to move, so that its magnetization vector N ′ is parallel to the magnetization vector N of the fixed magnet 3, but in an opposite direction, so as to loop the field lines magnetic. This amounts to putting the fixed 3 and mobile 4 magnets facing each other.
- This phenomenon creates a magnetic torque for returning the valve 2a to an equilibrium position E, materialized by the plane BB 'of FIG. 8.
- the valve is in its magnetic equilibrium position E, when it forms an angle 45 ° with 30658
- the magnetic return torque applied from the closed position to the magnetic equilibrium position, guarantees a minimum opening of the valve at 45 ° during the downstream blood flow phase.
- the return torque applied from the fully open position to the magnetic equilibrium position, makes it possible to guide the valve to this position, at the moment when the transvalvular pressure difference reverses, and thus minimize reflux.
- This example of magnetic assistance may also be suitable for the functional requirements of an aortic or mitral valve prosthesis, but will constitute a less optimal solution, because it is less specific.
- the activation system operates under the sole influence of mobile magnetic elements.
- the fixed magnetic elements of the seat are then non-existent or inactive or else produce a negligible influence compared to that produced by the mobile magnetic elements.
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Transplantation (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- External Artificial Organs (AREA)
- Magnetically Actuated Valves (AREA)
- Mechanically-Actuated Valves (AREA)
- Air-Flow Control Members (AREA)
- Lift Valve (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9707591-4A BR9707591A (pt) | 1996-02-20 | 1997-02-20 | Sistema de ativação de uma válvula cardìaca e válvula cardìaca ativada. |
AU20987/97A AU734016B2 (en) | 1996-02-20 | 1997-02-20 | Heart valve activation system and activated heart valve |
IL12572797A IL125727A0 (en) | 1996-02-20 | 1997-02-20 | Heart valve activation system and activated heart valve |
US08/894,513 US5961550A (en) | 1996-02-20 | 1997-02-20 | Heart valve activating system and activated heart valve |
EP97906229A EP0959817A1 (fr) | 1996-02-20 | 1997-02-20 | Systeme d'activation d'une valve cardiaque et valve cardiaque activee. |
JP9529853A JP2000504613A (ja) | 1996-02-20 | 1997-02-20 | 心臓弁駆動システム及び駆動された心臓弁 |
NO983703A NO983703L (no) | 1996-02-20 | 1998-08-13 | Aktiveringsanordning for hjerteventil, og aktivert hjerteventil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/02052 | 1996-02-20 | ||
FR9602052A FR2744909B1 (fr) | 1996-02-20 | 1996-02-20 | Systeme d'activation d'une valve cardiaque |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997030658A1 true WO1997030658A1 (fr) | 1997-08-28 |
Family
ID=9489373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1997/000312 WO1997030658A1 (fr) | 1996-02-20 | 1997-02-20 | Systeme d'activation d'une valve cardiaque et valve cardiaque activee. |
Country Status (13)
Country | Link |
---|---|
US (2) | US5814100A (fr) |
EP (1) | EP0959817A1 (fr) |
JP (1) | JP2000504613A (fr) |
KR (1) | KR19990087088A (fr) |
CN (1) | CN1213955A (fr) |
AU (1) | AU734016B2 (fr) |
BR (1) | BR9707591A (fr) |
CA (1) | CA2246645A1 (fr) |
FR (1) | FR2744909B1 (fr) |
HU (1) | HUP9901124A3 (fr) |
IL (1) | IL125727A0 (fr) |
NO (1) | NO983703L (fr) |
WO (1) | WO1997030658A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6206918B1 (en) | 1999-05-12 | 2001-03-27 | Sulzer Carbomedics Inc. | Heart valve prosthesis having a pivot design for improving flow characteristics |
KR100388936B1 (en) * | 2002-10-02 | 2003-06-25 | Newheart Bio Co Ltd | Artificial polymer valve |
US6638303B1 (en) | 1998-03-13 | 2003-10-28 | Carbomedics, Inc. | Heart valve prosthesis |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6402780B2 (en) * | 1996-02-23 | 2002-06-11 | Cardiovascular Technologies, L.L.C. | Means and method of replacing a heart valve in a minimally invasive manner |
SE508717C2 (sv) * | 1996-05-24 | 1998-11-02 | Atos Medical Ab | Röstprotes |
US6395024B1 (en) * | 1997-05-20 | 2002-05-28 | Triflo Medical, Inc. | Mechanical heart valve |
US6077299A (en) * | 1998-06-22 | 2000-06-20 | Eyetronic, Llc | Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma |
AU2001265264A1 (en) | 2000-05-31 | 2001-12-11 | Cardioclasp, Inc. | Devices and methods for assisting natural heart function |
US7201771B2 (en) | 2001-12-27 | 2007-04-10 | Arbor Surgical Technologies, Inc. | Bioprosthetic heart valve |
US7959674B2 (en) | 2002-07-16 | 2011-06-14 | Medtronic, Inc. | Suture locking assembly and method of use |
US20080086202A1 (en) * | 2002-09-27 | 2008-04-10 | Didier Lapeyre | Mechanical heart valve |
US8551162B2 (en) | 2002-12-20 | 2013-10-08 | Medtronic, Inc. | Biologically implantable prosthesis |
US8021421B2 (en) | 2003-08-22 | 2011-09-20 | Medtronic, Inc. | Prosthesis heart valve fixturing device |
US7556647B2 (en) | 2003-10-08 | 2009-07-07 | Arbor Surgical Technologies, Inc. | Attachment device and methods of using the same |
US7819131B2 (en) * | 2005-02-14 | 2010-10-26 | Cameron International Corporation | Springless compressor valve |
US7513909B2 (en) | 2005-04-08 | 2009-04-07 | Arbor Surgical Technologies, Inc. | Two-piece prosthetic valves with snap-in connection and methods for use |
WO2006130505A2 (fr) | 2005-05-27 | 2006-12-07 | Arbor Surgical Technologies, Inc. | Joint a collier pour valves cardiaques prothetiques et procedes d'utilisation associes |
US7967857B2 (en) | 2006-01-27 | 2011-06-28 | Medtronic, Inc. | Gasket with spring collar for prosthetic heart valves and methods for making and using them |
EP2023860A2 (fr) | 2006-04-29 | 2009-02-18 | Arbor Surgical Technologies, Inc. | Ensembles de valves cardiaques prosthétiques à composants multiples et appareil et procédés pour leur implantation |
US9523436B2 (en) * | 2007-02-12 | 2016-12-20 | Zahroof Valves, Inc. | Valve assembly and system |
US9179850B2 (en) | 2007-10-30 | 2015-11-10 | Neuropace, Inc. | Systems, methods and devices for a skull/brain interface |
US20090112278A1 (en) | 2007-10-30 | 2009-04-30 | Neuropace, Inc. | Systems, Methods and Devices for a Skull/Brain Interface |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (fr) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Dispositif de mesure de la concentration d'un soluté et procédés associés |
US9452045B2 (en) * | 2008-10-10 | 2016-09-27 | Peter Forsell | Artificial valve |
JP5580319B2 (ja) * | 2008-10-10 | 2014-08-27 | ミルックス・ホールディング・エスエイ | 改良型人工弁 |
US9211377B2 (en) | 2009-07-30 | 2015-12-15 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
WO2016199011A1 (fr) * | 2015-06-11 | 2016-12-15 | Ik-Interklimat S.P.A. | Soupape de compensation améliorée pour environnements avec une pression différente de la pression atmosphérique |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974854A (en) * | 1972-09-07 | 1976-08-17 | Kurpanek W H | Valve particularly adapted for utilization in controlling the flow of blood |
US4605408A (en) * | 1983-03-30 | 1986-08-12 | Universite Pierre Et Marie Curie Paris Vi | Artificial cardiac valve with active opening |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3370305A (en) * | 1965-05-28 | 1968-02-27 | Goott Bernard | Heart valve with magnetic hinge means |
US3959827A (en) * | 1972-08-08 | 1976-06-01 | Kaster Robert L | Heart valve prosthesis |
US3794854A (en) * | 1972-11-30 | 1974-02-26 | Rca Corp | Signal sensing and storage circuit |
CH608368A5 (en) * | 1976-05-20 | 1979-01-15 | Sulzer Ag | Implantable closure member |
US4276658A (en) * | 1977-11-02 | 1981-07-07 | St. Jude Medical, Inc. | Heart valve prosthesis |
US4245358A (en) * | 1979-01-24 | 1981-01-20 | Manoutcher Moasser | Nontraumatic prosthetic valve with magnetic closure |
USRE30507E (en) * | 1979-03-22 | 1981-02-10 | Heart valve prosthesis | |
US4328592A (en) * | 1979-08-07 | 1982-05-11 | Hemex, Inc. | Heart valve prosthesis |
DE3128704A1 (de) * | 1981-07-21 | 1983-02-10 | Peter Dr. 5012 Bedburg Küpper | Herzklappenprothese |
US4417360A (en) * | 1981-07-31 | 1983-11-29 | Manoutchehr Moasser | Nontraumatic prosthetic valve with magnetic closure |
FR2587614B1 (fr) * | 1985-09-23 | 1988-01-15 | Biomasys Sa | Valve cardiaque prothetique |
US4863460A (en) * | 1986-03-04 | 1989-09-05 | Sta-Set Corporation | Suture rings for heart valves |
US4769032A (en) * | 1986-03-05 | 1988-09-06 | Bruce Steinberg | Prosthetic valve and monitoring system and method |
US4657545A (en) * | 1986-04-29 | 1987-04-14 | Zibelin Henry S | Heart valve |
US4661107A (en) * | 1986-07-21 | 1987-04-28 | Fink Irving E | Heart valve |
US4979955A (en) * | 1988-06-06 | 1990-12-25 | Smith Robert M | Power assisted prosthetic heart valve |
US5045298A (en) * | 1988-11-04 | 1991-09-03 | Kabushiki Kaisha Kobe Seiko Sho | Carbon material and process for production thereof |
FR2642960B1 (fr) * | 1989-02-15 | 1994-02-25 | Dassault Breguet Aviation | Valve cardiaque prothetique |
US5135538A (en) * | 1989-09-29 | 1992-08-04 | General Motors Corporation | Electromagnetically controlled heart valve |
DE19529388C2 (de) * | 1995-08-10 | 1997-03-13 | Max Speckhart | Künstliche Herzklappe |
-
1996
- 1996-02-20 FR FR9602052A patent/FR2744909B1/fr not_active Expired - Fee Related
- 1996-08-09 US US08/694,580 patent/US5814100A/en not_active Expired - Fee Related
-
1997
- 1997-02-20 CA CA002246645A patent/CA2246645A1/fr not_active Abandoned
- 1997-02-20 KR KR1019980706476A patent/KR19990087088A/ko not_active Application Discontinuation
- 1997-02-20 BR BR9707591-4A patent/BR9707591A/pt not_active Application Discontinuation
- 1997-02-20 IL IL12572797A patent/IL125727A0/xx unknown
- 1997-02-20 CN CN97193204A patent/CN1213955A/zh active Pending
- 1997-02-20 JP JP9529853A patent/JP2000504613A/ja active Pending
- 1997-02-20 WO PCT/FR1997/000312 patent/WO1997030658A1/fr not_active Application Discontinuation
- 1997-02-20 HU HU9901124A patent/HUP9901124A3/hu unknown
- 1997-02-20 US US08/894,513 patent/US5961550A/en not_active Expired - Fee Related
- 1997-02-20 AU AU20987/97A patent/AU734016B2/en not_active Ceased
- 1997-02-20 EP EP97906229A patent/EP0959817A1/fr not_active Withdrawn
-
1998
- 1998-08-13 NO NO983703A patent/NO983703L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974854A (en) * | 1972-09-07 | 1976-08-17 | Kurpanek W H | Valve particularly adapted for utilization in controlling the flow of blood |
US4605408A (en) * | 1983-03-30 | 1986-08-12 | Universite Pierre Et Marie Curie Paris Vi | Artificial cardiac valve with active opening |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638303B1 (en) | 1998-03-13 | 2003-10-28 | Carbomedics, Inc. | Heart valve prosthesis |
US6206918B1 (en) | 1999-05-12 | 2001-03-27 | Sulzer Carbomedics Inc. | Heart valve prosthesis having a pivot design for improving flow characteristics |
KR100388936B1 (en) * | 2002-10-02 | 2003-06-25 | Newheart Bio Co Ltd | Artificial polymer valve |
Also Published As
Publication number | Publication date |
---|---|
JP2000504613A (ja) | 2000-04-18 |
US5814100A (en) | 1998-09-29 |
FR2744909B1 (fr) | 1998-05-07 |
NO983703L (no) | 1998-10-19 |
FR2744909A1 (fr) | 1997-08-22 |
CN1213955A (zh) | 1999-04-14 |
HUP9901124A2 (hu) | 1999-08-30 |
BR9707591A (pt) | 2000-01-04 |
IL125727A0 (en) | 1999-04-11 |
US5961550A (en) | 1999-10-05 |
EP0959817A1 (fr) | 1999-12-01 |
NO983703D0 (no) | 1998-08-13 |
CA2246645A1 (fr) | 1997-08-28 |
AU734016B2 (en) | 2001-05-31 |
AU2098797A (en) | 1997-09-10 |
HUP9901124A3 (en) | 2001-06-28 |
KR19990087088A (ko) | 1999-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997030658A1 (fr) | Systeme d'activation d'une valve cardiaque et valve cardiaque activee. | |
EP0220097B1 (fr) | Valve cardiaque prothétique | |
EP0383676B1 (fr) | Valve cardiaque prothétique | |
EP0283413A1 (fr) | Valve à au moins un volet basculant par rapport à des pivots élastiques | |
EP0121473B1 (fr) | Valve cardiaque artificielle à ouverture active | |
CA2458956C (fr) | Cintre pour vetement en matiere plastique a rigidite renforcee | |
EP0465383A1 (fr) | Valve cardiaque artificielle | |
EP2045496B1 (fr) | Vanne à clapet à pression equilibrée | |
EP0735837B1 (fr) | Machine automatique pour la preparation d'infusions de boissons chaudes | |
FR1464971A (fr) | Clapet utilisable notamment en chirurgie | |
EP0079844B1 (fr) | Prothèse valvulaire cardiaque | |
EP0810891A1 (fr) | Catheter a soupape a fente(s) axiale(s) bi-directionnelle(s) | |
EP0318351B1 (fr) | Valve cardiaque artificielle | |
EP3187410B1 (fr) | Dirigeable hydride a enveloppe exterieure souple et compartimentee | |
EP0884505A1 (fr) | Dispositif de transmission de mouvements à levier pivotant et vanne incorporant un tel dispositif | |
FR2503799A1 (fr) | Pompe peristaltique pour applications medicales | |
EP0639393B1 (fr) | Elément de fixation de ski alpin | |
WO2000053124A1 (fr) | Implant intraoculaire souple | |
FR2971574A1 (fr) | Soupape de commande d'un fluide | |
FR2954806A1 (fr) | Electrovanne de commutation notamment vanne de reglage de debit a commande electromagnetique pour une pompe haute pression de carburant | |
CH717035A1 (fr) | Valve cardiaque prothétique mécanique. | |
EP1548170A1 (fr) | Porte de tambour rotatif, notamment pour machine à laver et/ou sécher le linge | |
FR3138297A1 (fr) | Prothèse valvulaire cardiaque mécanique. | |
EP1364891A1 (fr) | Dispositif de décharge brusque d'air avec conduite d'éjection améliorée | |
FR2761447A1 (fr) | Electrovanne cyclee de regulation de debit de fluide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97193204.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08894513 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997906229 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2246645 Country of ref document: CA Ref document number: 2246645 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980706476 Country of ref document: KR Ref document number: PA/a/1998/006761 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1199800806 Country of ref document: VN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997906229 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980706476 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980706476 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997906229 Country of ref document: EP |